OncLive TV

Nazli Dizman, MD, discusses next steps planned for research with CBM588 in patients with renal cell carcinoma in the first line.

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Roger Li, MD, discusses safety data from the final analysis of the CORE-001 trial in BCG-unresponsive non–muscle-invasive bladder cancer.

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Andrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Bruce G. Haffty, MD, MS, FACR, FASTRO, discusses the use of radiation in node-positive breast cancer patients who convert to node-negative status after neoadjuvant chemotherapy.

Amitkumar Mehta, MD, discusses complexities and considerations around sequencing CAR T-cell therapies and bispecific antibodies in lymphoma.

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.